Kyle et al evaluated patients with monocloncal gammopathy of undetermined significance (MGUS). The authors are from the Mayo Clinic.
The risk of progression of MGUS to myeloma or related disorder is about 1% per year over long-term follow-up.
A patient with MGUS may develop:
(1) multiple myeloma or plasmacytoma
(2) non-Hodgkin's lymphoma with IgM serum monoclonal protein
(3) primary amyloidosis
(4) macroglobulinemia
(5) CLL
Risk factors for progression:
(1) initial concentration of the monoclonal protein
(2) IgM or IgA monocloncal protein (versus IgG)
Initial Monoclonal Protein
Progression Over 10 Years
Progression Over 20 Years
<=0.5 g/dL
6%
14%
1 g/dL
7%
1.5 g/dL
11%
25%
2.0 g/dL
20%
41%
2.5 g/dL
24%
49%
3.0 g/dL
34%
64%
To read more or access our algorithms and calculators, please log in or register.
Specialty: Hematology Oncology
